209 related articles for article (PubMed ID: 29211704)
1. Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
Shi XY; Ding W; Li TQ; Zhang YX; Zhao SC
Med Sci Monit; 2017 Dec; 23():5793-5802. PubMed ID: 29211704
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
Kumagai T; Wakimoto N; Yin D; Gery S; Kawamata N; Takai N; Komatsu N; Chumakov A; Imai Y; Koeffler HP
Int J Cancer; 2007 Aug; 121(3):656-65. PubMed ID: 17417771
[TBL] [Abstract][Full Text] [Related]
4. Modulation of radiation response by histone deacetylase inhibition.
Chinnaiyan P; Vallabhaneni G; Armstrong E; Huang SM; Harari PM
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):223-9. PubMed ID: 15850925
[TBL] [Abstract][Full Text] [Related]
5. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics.
Zhou X; Yang XY; Popescu NC
Int J Oncol; 2010 Apr; 36(4):999-1005. PubMed ID: 20198346
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells.
Gillenwater AM; Zhong M; Lotan R
Mol Cancer Ther; 2007 Nov; 6(11):2967-75. PubMed ID: 18025281
[TBL] [Abstract][Full Text] [Related]
8. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.
Lu YS; Kashida Y; Kulp SK; Wang YC; Wang D; Hung JH; Tang M; Lin ZZ; Chen TJ; Cheng AL; Chen CS
Hepatology; 2007 Oct; 46(4):1119-30. PubMed ID: 17654699
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
[TBL] [Abstract][Full Text] [Related]
11. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
[TBL] [Abstract][Full Text] [Related]
13. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
[TBL] [Abstract][Full Text] [Related]
14. Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells.
Seo SK; Jin HO; Lee HC; Woo SH; Kim ES; Yoo DH; Lee SJ; An S; Rhee CH; Hong SI; Choe TB; Park IC
Mol Pharmacol; 2008 Mar; 73(3):1005-12. PubMed ID: 18156316
[TBL] [Abstract][Full Text] [Related]
15. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Marrocco DL; Tilley WD; Bianco-Miotto T; Evdokiou A; Scher HI; Rifkind RA; Marks PA; Richon VM; Butler LM
Mol Cancer Ther; 2007 Jan; 6(1):51-60. PubMed ID: 17218635
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines.
Kisseberth WC; Murahari S; London CA; Kulp SK; Chen CS
Am J Vet Res; 2008 Jul; 69(7):938-45. PubMed ID: 18593248
[TBL] [Abstract][Full Text] [Related]
17. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment.
Huang L; Pardee AB
Mol Med; 2000 Oct; 6(10):849-66. PubMed ID: 11126200
[TBL] [Abstract][Full Text] [Related]
18. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer.
Arnold NB; Arkus N; Gunn J; Korc M
Clin Cancer Res; 2007 Jan; 13(1):18-26. PubMed ID: 17200334
[TBL] [Abstract][Full Text] [Related]
19. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro.
Sonnemann J; Bumbul B; Beck JF
Mol Cancer Ther; 2007 Nov; 6(11):2976-84. PubMed ID: 18025282
[TBL] [Abstract][Full Text] [Related]
20. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.
Emanuele S; Lauricella M; Carlisi D; Vassallo B; D'Anneo A; Di Fazio P; Vento R; Tesoriere G
Apoptosis; 2007 Jul; 12(7):1327-38. PubMed ID: 17351739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
